Company Information

Company Amgen, Inc.
United States of America
Pharmaceuticals & Biotechnology
Publicly Listed
Global Compact Status:
Participant Since
28 April 2017
Letter of Commitment
Next Communication on Progress (COP) due on:
31 July 2024

Financial Information

Communication On Progress

Published On Title Level/Status
28-Apr-2022 2021 Communication on Progress Active
18-May-2021 Communication on Progress Active
19-May-2020 Amgen 2019 Communication on Progress Active
20-May-2019 2018 Communication on Progress Active
22-May-2018 Amgen 2017 Communication on Progress Active
09-Jan-2018 Reporting Cycle Adjustment Not applicable

Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.

Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP, for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.